Meta description: regulatory update on CHAPERONE AI and CKMiq AI in cardiovascular kidney and metabolic health trials for acute myocardial infarction and related conditions.
On February 11 2026 a multi sponsor program described in ClinicalTrials.gov as NCT07403669 continues to recruit participants. The study combines a software based intervention named CHAPERONE AI with a hardware device called CKMiq AI. Sponsors span academic and health care partners and technology companies. The new data points highlight how regulators may approach integrated digital devices in high risk cardiometabolic care. This article presents the facts and what this means for regulators health care providers and researchers.
What changed for regulatory oversight?
The entry describes a protocol that uses software and hardware components in a single trial. The presence of a device CKMiq AI together with a software based CHAPERONE AI indicates an integrated solution that regulators may review as a combined product. The trial status is recruiting which means the project is at a stage where documentation of intended use design controls risk management and post market surveillance plans would be expected. The description aligns with a research protocol that is not yet seeking marketing authorization. The information is sourced from the ClinicalTrials.gov record and is used by the sponsor and sites to coordinate oversight across multiple institutions.
What is the trial context and patient population?
The conditions listed include acute myocardial infarction heart failure diabetes mellitus and kidney disease. This combination points to a population at high cardiometabolic risk that may benefit from integrated digital and device based tools. The aim is to support risk reduction and clinical decision making while maintaining close regulatory attention given the serious nature of the endpoints. The source text does not include data on outcomes but the setup suggests rigorous follow up and predefined endpoints aligned with standard research practice.
What are CHAPERONE AI and CKMiq AI in this program?
CHAPERONE AI is described as an other intervention in the trial record. CKMiq AI is described as a device and is listed alongside the software based tool. The pairing illustrates a portfolio approach to care that integrates digital assistance with a hardware element. The trial framing does not provide performance results. In regulatory terms this signals a need for clear intended use documentation device safety specifications software validation and risk management alignment across the system. The entry reflects the growing attention to integrated solutions in cardiometabolic care and the regulatory implications of software as a medical device in line with MDR Annex XIV expectations.
Who sponsors and what is the status of the program?
The sponsor list includes Aventyn Inc Dignity Health Arizona Heart Foundation Arizona State University University of Arizona University of Phoenix College of Nursing Creighton School of Medicine in Phoenix Karolinska University Hospital Partnership for Economic Innovation AZ Kanasu Labs and Intel Corporation. This broad collaboration supports a high level of oversight complexity and governance across sites and functions. The recruiting marker indicates that enrollment is active. Clinical sites and investigators will be required to document compliance with applicable regulations and ensure data integrity and safety standards are maintained as the study proceeds.
Where is enrollment and what is the status
Enrollment is described as Recruiting in the source text. That status denotes ongoing screening and site based participation. Investigators can find more procedural detail on the ClinicalTrials.gov entry referenced by the identifier NCT07403669. The page will provide eligibility criteria and endpoint definitions. Stakeholders should monitor updates that may alter site participation or enrollment pace as the trial advances through phases.
What safety considerations are noted
Safety considerations in a protocol that includes a device and software focus on risk management software validation and device performance. The MDR framework calls for documentation of hazard analysis and risk controls and for ongoing surveillance. The source text does not report results but outlines the framework used to evaluate safety and performance in a high risk patient group. Clinicians regulatory staff and manufacturers should align their plans with MDR requirements and ensure communication across all participants and sites.
What the regulatory path implies for practice and oversight
Practitioners and regulators should track evolving guidance for software as a medical device and integrated device software systems. The trial context demonstrates how teams may align software tools with hardware devices to support complex cardiometabolic care. The likely regulatory path will require detailed statements of intended use performance claims risk management artifacts and post market plans if advancement toward clearance or approval occurs. Stakeholders should prepare for changes in documentation and oversight practices as the field evolves.
FAQ
- What is the CHAPERONE AI entry in this trial
- What is CKMiq AI in this program
- Where can I find official trial information
Conclusion
The update indicates that regulatory oversight is progressing on an integrated software and device trial for high risk cardiometabolic patients. Regulators and providers should monitor documentation and status using the ClinicalTrials.gov entry.
Disclaimer
This article is for professional information only and is not legal advice. It summarizes regulatory concepts based on the source text.
For full information about the announcement see the link below.
https://clinicaltrials.gov/study/NCT07403669?term=medical+device